Skip to content

Pilot Clinical Trial of an Integrative Intervention to Improve Critically Ill Patients' Delirium and Related Outcomes

Delirium

Methodology: Pilot randomized controlled trial with 1 intervention and 1 parallel standard care group to assess the feasibility and treatment effect of a multimodal integrative intervention for delirium prevention and associated detrimental effects.

Duration: 2 years, two months. Study Center(s): Multi-center (2 sites) Aim: To assess feasibility and measures of effect of a multimodal intervention consisting of relaxation with guided imagery (RGI), and moderate pressure massage on physiological and psychological outcomes of critically ill patients.

Objectives: a) assess clinical trial feasibility with pre-defined goals (enrollment, randomization, adherence, timing of intervention, workload), b) calculate estimates and variance of treatment effect across outcome measures, c) calculate confidence intervals (CI) of incidence proportions, means and standard deviation (SD) of outcome measures in study groups., d) explore underlying physiological mechanisms of efficacy Number of Subjects: 60 participants per arm. Total: 120 participants Diagnosis and Main Inclusion Criteria: Critical illness Inclusion criteria: a) Age over 18 years, b) ICDSC:0-3. Exclusion Criteria: Patients: a) with expected ICU LOS\< 72 hours, b) with acute neurological illness/ trauma, persistent sedation or coma, c) with current history of severe mental health problems and dementia, as per history and psychiatrist assessment, c) with hearing impairment or conditions not permitting use of headphones, e) on neuro-muscular blockers, f) with substance/ alcohol withdrawal, g) enrolled in trials of sedatives, antipsychotics.

Intervention: REPOSE intervention (a multimodal relaxation intervention) It includes: a) relaxation and guided imagery (RGI) (40 min, headphones), b) a brief moderate pressure massage session (massage: 15 min). RGI involves: a) guided relaxation, b) a structured guided imagery script and c) music for 15 min (Mozart piano sonata KV283, G major (2 3) II Andante). Duration of administration: Up to 5 days while participants still in the ICU.

Reference therapy: Standard care plus placebo to maintain blinding. Statistical Methodology: Outcomes will be analyzed longitudinally over 5 days by logistic regression model based on generalized estimating equations (GEE) with AR(1) correlation structure. Confidence intervals will be presented with estimated effects. Primary analysis will be based on all available data utilizing data from all assessments.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* patients hospitalized in one of the study Intensive Care Units (ICUs)
* Age over 18 years
* Intensive Care Delirium Screening Checklist (ICDSC):0-3
* patients enrolled in other investigative trials not involving sedative, psychoactive medications

Exclusion Criteria:

* patients with expected Intensive Care Unit length of stay \< 72 hours
* patients with acute neurological illness/ trauma, persistent sedation or coma
* patients with current history of severe mental health problems and dementia, as per history and psychiatrist assessment
* patients with hearing impairment or conditions not permitting use of headphones
* patients on neuro-muscular blocker medications
* patients with substance/ alcohol withdrawal
* patients enrolled in trials of sedatives, antipsychotics

Lieu de l'étude

Misreicordia Hospital
Misreicordia Hospital
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Elisavet Papathanasoglou, PhD

Étude parrainée par
University of Alberta
Participants recherchés
Plus d'informations
ID de l'étude: NCT02905812